期刊文献+

载雄激素受体三螺旋形成寡核苷酸PEG-PLGA纳米粒子的制备与应用 被引量:4

Preparation and Primary Application of Androgen Receptor Triplex-forming Oligonucleotides Loaded PEG-PLGA Nanoparticles
下载PDF
导出
摘要 【目的】以生物可降解材料聚乙二醇-聚乳酸聚乙醇酸共聚物(PEG-PLGA)制备载雄激素受体三螺旋形成寡核苷酸的纳米粒子(TFO-NPs),并初步探讨其对前列腺癌LNCaP细胞的生长抑制作用。【方法】采用改良自乳化溶剂挥发法(modified-SESD)制备TFO-NPs,对其形态、包封率、载药量及体外释放特点进行鉴定。倒置荧光显微镜观察LNCaP细胞对TFO-NPs的摄取情况,四唑盐(MTT)法测定体外细胞毒作用。【结果】制备的TFO-NPs呈球形、大小均匀,平均粒径128nm,平均包封率和载药量分别为72.28%和1.02%,在体外具有缓释作用。LNCaP细胞对TFO-NPs的摄取率显著高于裸TFO。TFO-NPs对LNCaP细胞的抑制作用明显强于裸TFO(P<0.05),抑制率分别为61.2%±6.5%和20.7%±3.1%。【结论】本法制备的TFO-NPs理化性质优良,在体外能够有效抑制LNCaP细胞的增殖。 [Objective] To prepare androgen receptor gene TFO loaded nanoparticles (TFO-NPs) with biodegradable material poly (ethylene glycol)-poly (lactide-co-glycolide) (PEG-PLGA) and to investigate their inhibitory effect on LNCaP cells in vitro. [Methods] TFO-NPs were prepared by modified spontaneous emulsion solvent diffusion method (modified-SESD). Then their morphology, encapsulation rate, drug loading efficiency and drug released characteristics were identified. The uptake of TFO-NPs by LNCaP cells was observed by an inverted florescent microscope, and the cytotoxicity to LNCaP cells was determined by MTT assay. [Results] The TFO-NPs were spherical, uniform, with mean diameter of 128 nm. Their encapsulation rate and drug loading efficiency of TFO- NPs were 72.28% and 1.02%, respectively. The release test in vitro showed significant sustained release. The cellular uptake rate of TFO-NPs was markedly higher than that of naked TFO. The inhibitory effect on LNCaP cells of TFO-NPs was significantly obvious than that of naked TFO(P 〈 0.05), and their inhibitory rates were 61.2% ± 6.5% and 20.7% ± 3.1%, respectively. [Conclusions] The physicochemical properties of TFO-NPs prepared by modified-SESD method are excellent. TFO-NPs can inhibit LNCaP cells proliferation efficiently in vitro.
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2008年第5期602-605,共4页 Journal of Sun Yat-Sen University:Medical Sciences
基金 广东省自然科学基金(200501697) 广州市科技计划项目(2007Z3-E0201)
关键词 聚乙二醇-聚乳酸聚乙醇酸共聚物 改良自乳化溶剂挥发法 纳米粒 三螺旋形成寡聚核苷酸 前列腺癌 PEG-PLGA modified-SESD nanoparticles triplex-forming oligonucleotide prostatic cancer
  • 相关文献

参考文献10

  • 1周嘉嘉,陈汝福,卢红伟,唐启彬,周泉波,张黎明.两亲多糖纳米胶束作为药物缓释载体的制备及释药研究[J].中山大学学报(医学科学版),2006,27(6):667-671. 被引量:14
  • 2何祥梁,叶海宁,何东华,马中富,廖晓星,詹红,熊艳,荆小丽.包裹E1A基因的纳米粒子制备及转染人肺腺癌细胞A549实验研究[J].热带医学杂志,2007,7(6):519-521. 被引量:2
  • 3平其能.现代药剂学[M].北京:中国医药科技出版社,1999. 625-639
  • 4张勇,陈维真,谢瑶,高锦辉.雄激素受体三螺旋形成寡核苷酸抗前列腺癌细胞增殖的研究[J].中华核医学杂志,2005,25(2):97-99. 被引量:3
  • 5Murakami H, Kobayashi M, Takeuchi H. Preparation of poly (DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method [J]. Int J Pharm, 1999, 187(2) : 143-152.
  • 6Yang AS, Yang L, Liu W, et al. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: Preparation and in vivo evaluation [J]. Int J Pharm, 2007,331( 1 ) : 123-132.
  • 7Avgoustakis K, Beletsi A, Panagi Z, et al. PLGA- mPEG nanopartieles of eisplatin: in vitro nanopartiele degradation, in vitro drug release and in vivo drug residence in blood properties [J]. J Cont Res, 2002, 79(1-3) : 123-135.
  • 8Cohen-Sacks H, Najajreh Y, Tchaikovski V, et al. Novel PDGFβR antisense encapsulated in polymeric nanoparticles for the treatment of restenosis [J]. Gene Therapy, 2002,9(23) : 1607-1616.
  • 9Panyam J, Zhou WZ, Prabha S, et al. Rapid endolysosomal escape of poly (D, L-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery [J]. FASEB J, 2002, 16(10) : 1217-1226.
  • 10陈波,熊利华,华平,廖洪映,殷香保,汤志华,蒙荣森,邓伟.纳米血管生成素-2小干扰RNA质粒制备及功能研究[J].中山大学学报(医学科学版),2005,26(2):146-150. 被引量:2

二级参考文献41

共引文献21

同被引文献29

  • 1Errico C, Bartoli C, Chiellini F, Chiellini E. Poly (hydroxyalkanoates)-based polymeric nanoparticles for drug delivery. J Biomed Bioteehnol, 2009,doi:10.1155/2009/ 571702.
  • 2Wu SC, Chang JK, Wang CK, et al. Enhancement of chondrogenesis of human adipose derived stem cells in a hyaluronan-enriched mieroenvironment. Biomaterials, 2010,31 (4) :631-640.
  • 3Kakizawa Y, Nishio R, Hirano T, et al. Controlled release of protein drugs from newly developed amphiphilic polymer-based microparticles composed of nanoparticles. Journal of Controlled Release, 2009 Oct 3. [Epub ahead of print ].
  • 4Li Y, Pei Y, Zhang X, et al. PEGylated PLGA nanopartieles as protein carriers: synthesis, preparation and biodistribution in rats. Journal of Controlled Release, 2001,71 (2) :203-211.
  • 5Lucienne J J. The targeted delivery of cancer drugs across the blood-brain barrier:chemical modifications of drugs or drug-nanoparticales? Drug Discovery Today, 2008,13 (23-24) : 1099-1106.
  • 6Luan X, Bodmeier R. In situ forming microparticle system for controlled delivery of leuprolide acetate: Influence of the formulation and processing parameters. European Journal of Pharmaceutical Sciences, 2006,27(2-3) : 143-149.
  • 7Gulyaev AE, Gelperina SE, Skidan IN et al. Significant transport of doxorubicin into the brain with polysorbate 80- coated nanoparticles. Pharmaceutical Research, 1999,16 (10) : 1564-1569.
  • 8Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx, 2005,2( 1 ) : 108-119.
  • 9Vandervoort J, Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int J Pharm, 2002,238 (1-2) : 77-92.
  • 10Xie S, Wang S, Zhao B, et al. Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2008,67(2) : 199-204.

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部